Our press releases

News Our press releases

Allecra Announces Initiation of a Phase 2 Clinical Trial for its Novel Antibiotic to Treat Resistant Bacterial Infections

in portfolio news

Allecra’s novel ß-lactamase inhibitor AAI101, co-administered with the powerful ß-lactam cefepime, is to be evaluated in patients for its potential to combat hospital-acquired, resistant Gram-negative infections

Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics to combat drug-resistant bacterial infections, today announces initiation of a Phase 2 clinical trial to evaluate the efficacy and safety of the combination cefepime/AAI101 for treatment of complicated urinary tract infections (cUTI).